Govt urged to end propaganda projecting India as major producer of spurious drugs

24 February 2010

Concerned over the propaganda being orchestrated by the vested interests that around 20%-25% of drugs produced in India are spurious, the country's pharmaceutical industry has asked the government to come out strongly with the real picture in this regard to set the record straight once and for all.

Industry sources quoted by PharmaBiz said that the sector raised this issue with Union Health Minister Ghulam Nabi Azad when he was in Mumbai recently. The industry expressed its displeasure over the repeated projection of Indian pharmaceutical industry as the major producers of spurious drugs in the world by the vested interests including some international organizations.

Some time back, the trade association Assocham had announced that the spurious drugs were growing at 20%-25% in the country and a substantial percentage of Indian drugs are spurious. Subsequently, several national and international organizations had quoted the Assocham figure to tarnish the image of Indian drugmakers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical